Mr. Brooke Yakatan joined IRISYS in 2014. His responsibilities at IRISYS include the overseeing and maintaining of GMP compliance in both small- and large-scale manufacturing campaigns ranging from Phase 1 and Phase 2 to commercial products.
Mr. Xie joined IRISYS in 2014 and is in charge of the Company’s finance, accounting and tax functions. He is responsible for financial planning and reporting, budgeting, cash management, payroll, internal control and tax filing and reporting.
Dr. Nikoulin established and directs the R&D and manufacturing capabilities for all dosage forms including nanoparticle-based drug delivery systems at IRISYS since joining the Company in 2013.
Ms. Karpinski joined IRISYS in 2014 and is responsible for managing people and activities that are at the hub of the organization.
Mr. Scotti was appointed Vice President, Business Development at IRISYS in 2015 after previously serving on our Board of Directors from 2007 until 2012.
Dr. Giannini has more than 30 years of pharmaceutical industry experience. His breadth of knowledge includes development of a wide range of dosage forms such as controlled/extended release solids, oral liquids, and injectables.
Dr. Yakatan has served as Chairman & CEO of IRISYS since founding the Company in 1996. In addition to his leadership and oversight of IRISYS’ operations, Dr. Yakatan personally heads our Strategic Consulting services.
Dr. Wang joined IRISYS in 2009. Her responsibilities include providing technical and quality guidance via directly overseeing quality control and regulatory filings.